Evodiamine inhibits the proliferation of leukemia cell line K562 by regulating peroxisome proliferators-activated receptor gamma (PPARγ) pathway

References

• Meng JJ, Fan YH, Su MZ, et al. WLIP derived from Lasiosphaera fenzlii Reich exhibits anti-tumor activity and induces cell cycle arrest through PPAR-γ associated pathways. Int Immunopharmacol 2014;19:37–44
   PubMed Web of Science ®Google Scholar
• Zhang X, Zhao WE, Hu LQ, et al. Carotenoids inhibit proliferation and regulate expression of peroxisome proliferators-activated receptor gamma (PPARγ) in K562 cancer cells. Arch Biochem Biophys 2011;512:96–106
   PubMed Web of Science ®Google Scholar
• Feige JN, Gelman L, Michalik L, et al. From molecular action to physiological outputs: peroxisome proliferator-activated receptors are nuclear receptors at the crossroads of key cellular functions. Prog Lipid Res 2006;45:120–59
   PubMed Web of Science ®Google Scholar
• Dubuquoy L, Dharancy S, Nutten S, et al. Role of peroxisome proliferator-activated receptor gamma and retinoid X receptor heterodimer in hepatogastroenterological diseases. Lancet 2002;360:1410–8
   PubMed Web of Science ®Google Scholar
• Mandard S, Patsouris D. Nuclear control of the inflammatory response in mammals by peroxisome proliferator-activated receptors. PPAR Res 2013;2013:613864
   PubMed Web of Science ®Google Scholar
• Dahabreh DF, Medh JD. Activation of peroxisome proliferator activated receptor gamma results in an atheroprotective apolipoprotein profile in HepG2 cells. Adv Biol Chem 2012;2:218–25
   PubMedGoogle Scholar
• Theocharisa S, Margeli A, Kouraklis G. Peroxisome proliferator activated receptor gamma ligands as potent antineoplastic agents. Curr Med Chem Anticancer Agents 2003;3:239–51
   PubMedGoogle Scholar
• Liu JJ, Huang RW, Lin DJ, et al. Expression of surviving and bax/bcl-2 in peroxisome proliferator activated receptor-gamma ligands induces apoptosis on human myeloid leukemia cells in vitro. Ann Oncol 2005;16:455–9
   PubMed Web of Science ®Google Scholar
• Yin F, Wakino S, Liu Z, et al. Troglitazone inhibits growth of MCF-7 breast carcinoma cells by targeting G1 cell cycle regulators. Biochem Biophys Res Commun 2001;286:916–22
   PubMed Web of Science ®Google Scholar
• Kubota T, Koshizuka K, Williamson EA, et al. Ligand for peroxisome proliferator-activated receptor gamma (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo. Cancer Res 1998;58:3344–52
   PubMed Web of Science ®Google Scholar
• Chang TH, Szabo E. Induction of differentiation and apoptosis by ligands of peroxisome proliferator-activated receptor gamma in non-small cell lung cancer. Cancer Res 2000;60:1129–38
   PubMed Web of Science ®Google Scholar
• Sporn MB, Suh N, Mangelsdorf DJ. Prospects for prevention and treatment of cancer with selective PPARgamma modulators (SPARMs). Trends Mol Med 2001;7:395–400
   PubMed Web of Science ®Google Scholar
• Tian HY, Yu ZC. Resveratrol induces apoptosis of leukemia cell line K562 by modulation of sphingosine kinase-1 pathway. Int J Clin Exp Pathol 2015;8:2755–62
   PubMed Web of Science ®Google Scholar
• Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2012 update on diagnosis, monitoring, and management. Am J Hematol 2012;87:1037–45
   PubMed Web of Science ®Google Scholar
• Rumjanek VM, Vidal RS, Maia RC. Multidrug resistance in chronic myeloid leukaemia: how much can we learn from MDR-CML cell lines? Biosci Rep 2013;33:e00081
   Web of Science ®Google Scholar
• Damery S, Gratus C, Grieve R, et al. The use of herbal medicines by people with cancer: a cross-sectional survey. Br J Cancer 2011;104:927–33
   PubMed Web of Science ®Google Scholar
• Yin SY, Wei WC, Jian FY, Yang NS. Therapeutic applications of herbal medicines for cancer patients. Evid Based Complement Alternat Med 2013;2013:302426
   PubMed Web of Science ®Google Scholar
• Chai S, To KK, Lin G. Circumvention of multi-drug resistance of cancer cells by Chinese herbal medicines. Chin Med 2010;5:1–9
   PubMedGoogle Scholar
• Kobayashi Y. The nociceptive and anti-nociceptive effects of evodiamine from fruits of Evodia rutaecarpa in mice. Planta Med 2003;69:425–8
   PubMed Web of Science ®Google Scholar
• Kobayashi Y, Nakano Y, Kizaki M, et al. Capsaicin-like anti-obese activities of evodiamine from fruits of Evodia rutaecarpa, a vanilloid receptor agonist. Planta Med 2001;67:628–33
   PubMed Web of Science ®Google Scholar
• Ogasawara M, Suzuki H. Inhibition by evodiamine of hepatocyte growth factor-induced invasion and migration of tumor cells. Biol Pharm Bull 2004;27:578–82
   PubMed Web of Science ®Google Scholar
• Ko HC, Wang YH, Liou KT, et al. Anti-inflammatory effects and mechanisms of the ethanol extract of Evodia rutaecarpa and its bioactive components on neutrophils and microglial cells. Eur J Pharmacol 2007;555:211–17
   PubMed Web of Science ®Google Scholar
• Shin YW, Bae EA, Cai XF, et al. In vitro and in vivo antiallergic effect of the fructus of Evodia rutaecarpa and its constituents. Biol Pharm Bull 2007;30:197–99
   PubMed Web of Science ®Google Scholar
• Yang ZG, Chen AQ, Liu B. Antiproliferation and apoptosis induced by evodiamine in human colorectal carcinoma cells (COLO-205). Chem Biodivers 2009;6:924–93
   PubMed Web of Science ®Google Scholar
• Huang H, Zhang Y, Liu X, et al. Acid sphingomyelinase contributes to evodiamine-induced apoptosis in human gastric cancer SGC-7901 cells. DNA Cell Biol 2011;30:407–12
   PubMed Web of Science ®Google Scholar
• Yang L, Liu X, Wu D, et al. Growth inhibition and induction of apoptosis in SGC-7901 human gastric cancer cells by evodiamine. Mol Med Rep 2014;9:1147–52
   PubMed Web of Science ®Google Scholar
• Yang J, Wu LJ, Tashino S, et al. Protein tyrosine kinase pathway-derived ROS/NO productions contribute to G2/M cell cycle arrest in evodiamine-treated human cervix carcinoma HeLa cells. Free Radic Res 2010;44:792–802
   PubMed Web of Science ®Google Scholar
• Zhu LH, Liu XD, Tan YH, et al. Proliferation inhibited and apoptosis-inducted effects of evodiamine on human hepatoma cell line HepG2. Chin Pharmacol Bull 2009;25:79–82
   Google Scholar
• Kan SF, Huang WJ, Lin LC, Wang PS. Inhibitory effects of evodiamine on the growth of human prostate cancer cell line LNCaP. Int J Cancer 2004;110:641–51
   PubMed Web of Science ®Google Scholar
• Wang C, Li S, Wang MW. Evodiamine-induced human melanoma A375-S2 cell death was mediated by PI3K/Akt/caspase and Fas-L/NF-kappaB signaling pathways and augmented by ubiquitin-proteasome inhibition. Toxicol In Vitro 2010;24:898–904
   PubMed Web of Science ®Google Scholar
• Ogasawara M, Matsunaga T, Takahashi S, et al. Antiinvasive and metastatic activities of evodiamine. Biol Pharm Bull 2002;25:1491–3
   PubMed Web of Science ®Google Scholar
• Liao CH, Pan SL, Guh JH, et al. Antitumor mechanism of evodiamine, a constituent from Chinese herb Evodiae fructus, in human multiple-drug resistant breast cancer NCI/ADR-RES cells in vitro and in vivo. Carcinogenesis 2005;26:968–75
   PubMed Web of Science ®Google Scholar
• Yang CM, Lu IH, Chen HY, Hu ML. Lycopene inhibits the proliferation of androgen-dependent human prostate tumor cells through activation of PPARγ-LXRα-ABCA1 pathway. J Nutr Biochem 2012;23:8–17
   PubMed Web of Science ®Google Scholar
• Zhao H, Gu H, Zhang H, et al. PPARγ-dependent pathway in the growth-inhibitory effects of K562 cells by carotenoids in combination with rosiglitazone. Biochim Biophys Acta 2014;1840:545–55
   PubMed Web of Science ®Google Scholar
• Massague J. G1 cell-cycle control and cancer. Nature 2004;432:298–306
   PubMed Web of Science ®Google Scholar
• Besson A, Dowdy SF, Roberts JM. CDK inhibitors: cell cycle regulators and beyond. Dev Cell 2008;14:159–69
   PubMed Web of Science ®Google Scholar
• Dai M, Al-Odaini AA, Fils-Aimé N, et al. Cyclin D1 cooperates with p21 to regulate TGFβ-mediated breast cancer cell migration and tumor local invasion. Breast Cancer Res 2013;15:R49
   PubMed Web of Science ®Google Scholar
• Lamb J, Ramaswamy S, Ford HL, et al. A mechanism of cyclin D1 action encoded in the patterns of gene expression in human cancer. Cell 2003;114:323–34
   PubMed Web of Science ®Google Scholar
• Lamb J, Ewen ME. Cyclin D1 and molecular chaperones: implications for tumorigenesis. Cell Cycle 2003;2:525–7
   PubMed Web of Science ®Google Scholar
• Smith AG, Beaumont KA, Smit DJ, et al. PPARgamma agonists attenuate proliferation and modulate Wnt/beta-catenin signalling in melanoma cells. Int J Biochem Cell Biol 2009;41:844–52
   PubMed Web of Science ®Google Scholar